Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Douglas Carl Behenna"'
Autor:
Kephart Susan Elizabeth, Tran Khanh Tuan, Kevin Daniel Freeman-Cook, Sherry Niessen, James Solowiej, Buwen Huang, Qin Zhang, Douglas Carl Behenna, Inish O'Doherty, Sacha Ninkovic, Rose Ann Ferre, Andrea Hui, Nichol Miller, Jordan Carelli, Lisa Nguyen, Brion W. Murray, Robert Louis Hoffman, John Lapek, Rhys M. Jones, Meirong Xu, Stephen Dann, Sutton Scott Channing, Asako Nagata, Nanni Huser, Ravi Visswanathan, Zehnder Luke Raymond, Elaine E. Tseng, Britton Boras, You-Ai He, Michele McTigue, Wade Diehl, Cathy Zhang, Martha A. Ornelas
Publikováno v:
Journal of medicinal chemistry. 64(13)
Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK isoforms represents an opportunity to expand to add
Autor:
Meirong Xu, Koleen Eisele, Douglas Carl Behenna, John Chionis, Sutton Scott Channing, Cathy Zhang, Ping Wei, Ravi Visswanathan, Stephen Dann, B Jessen, Robert M. Hoffman, Britton Boras, Kevin Daniel Freeman-Cook, Michael A. White, Qin Zhang, Brion W. Murray, Jing Yuan, Sacha Ninkovic, Scott L. Weinrich, Nanni Huser, Jim Solowiej, Nichol Miller, Todd VanArsdale, Chaoting Liu
Publikováno v:
Cancer Research. 79:P6-20
This abstract was withdrawn by the authors. Citation Format: Dann S, Chionis J, Eisele K, Zhang Q, Liu C, Yuan J, Miller N, Murray B, Xu M, Solowiej J, Wei P, Weinrich S, Sutton S, Behenna D, Ninkovic S, Hoffman R, Freeman-Cook K, Jessen B, Huser N,
Autor:
Ben Bolaňos, Sherry Niessen, Martha A. Ornelas, Paulina Delgado Cuenca, Douglas Carl Behenna, Lawrence G. Lum, Prakash B. Palde, Tran Khanh Tuan, Kevin Ryan, Stephen Kaiser, Marissa Smith, Lianglin Zhang, Todd VanArsdale, Al Stewart, Ketan S. Gajiwala
Publikováno v:
The Journal of Biological Chemistry
Poly-ADP-ribosyltransferases play a critical role in DNA repair and cell death, and poly(ADP-ribosyl) polymerase 1 (PARP1) is a particularly important therapeutic target for the treatment of breast cancer because of its synthetic lethal relationship
Autor:
Xinmeng Jasmine Mu, Meirong Xu, Shahram Salek-Ardakani, Cinthia Costa-Jones, Lisa Nguyen, James Solowiej, David Looper, Scott L. Weinrich, Robert Louis Hoffman, Sutton Scott Channing, Sacha Ninkovic, Kephart Susan Elizabeth, Sherry Niessen, John Chionis, Jadwiga Bienkowska, Kevin Daniel Freeman-Cook, Rose Ann Ferre, John Lapek, Cecilia Oderup, Jordan Carelli, Cathy Zhang, Nanni Huser, Elizabeth A. McMillan, Asako Nagata, Martha A. Ornelas, Brion W. Murray, Douglas Carl Behenna, Koleen Eisele, Todd VanArsdale, Zhou Zhu, Zhengyan Kan, Chaoting Liu, Nichol Miller, Zehnder Luke Raymond, Michael A. White, Ying Ding, Nathan V. Lee, Jonathan Almaden, Qin Zhang, Tran Khanh Tuan, Ping Wei, Stephen Dann, Britton Boras, Tim S. Wang, Ravi Visswanathan, You-Ai He, Michele McTigue, Elizabeth Wilson
Publikováno v:
Cancer Cell. 39:1404-1421.e11
Summary The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to discover PAL resistance mechanisms in preclinical models and through analys
Autor:
Chengyi Zhang, Sujin Cho-Schultz, Tran Khanh Tuan, Manli Shi, Rose Ann Ferre, Sherry Niessen, Sajiv Krishnan Nair, Douglas Carl Behenna, Dac M. Dinh, Elaine E. Tseng, Theodore O. Johnson, Cheng Hengmiao, Ru Zhou, Michael Zientek, T. Eric Ballard, Brion W. Murray, Suvi T. M. Orr, James Solowiej, Jennifer Lafontaine, Jean Joo Matthews, Scott L. Weinrich, Paolo Vicini, Deal Judith G, Longqing Liu, John Charles Kath, Pairish Mason Alan, Simon Paul Planken, Louise Bernier, Deepak Dalvie, Yiqin Luo, Martin Paul Edwards, Asako Nagata, Hong Shen, Neal W. Sach, Yuli Wang, Ketan S. Gajiwala, Shuibo Xin, Simon Bailey, Chau Almaden, Robert Steven Kania, Michelle Hemkens
Publikováno v:
Journal of Medicinal Chemistry. 60:3002-3019
Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance me
Autor:
Michael R. Lazear, Sherry Niessen, Shuyan Lu, Sabrina Barbas, Zachary E. Potter, Melissa M. Dix, Douglas Carl Behenna, Matthew Merrill Hayward, Kevin Ryan, Simon Paul Planken, John Charles Kath, Benjamin F. Cravatt, Oleg Brodsky, Ketan S. Gajiwala, Chau Almaden, RoseAnn Ferre
Publikováno v:
Cell Chemical Biology. 24:1388-1400.e7
Summary Patients with non-small cell lung cancers that have kinase-activating epidermal growth factor receptor (EGFR) mutations are highly responsive to first- and second-generation EGFR inhibitors. However, these patients often relapse due to a seco